TBA Law Blog


Posted by: Katharine Heriges on Aug 5, 2016

Attorney General Herbert Slatery announced today that Tennessee, 48 other states and the District of Columbia have reached an agreement with Cephalon Inc. and affiliated companies, now a part of Teva Pharmaceutical Industries, following alleged anti-competitive conduct. The $125 million settlement concludes an investigation into a scheme by Cephalon to block generic competition to its sleep-disorder drug, Provigil. Cephalon prevented competition by filing patent infringement lawsuits against potential competitors, and then paid those competitors to delay the sale of their generic versions of the drug. In total, the states will receive $35 million for distribution to consumers who purchased Provigil. Tennessee and its consumers will receive an estimated $3.32 million.